cerebral vasospasm Delayed cerebral ischemia
Conditions
Interventions
Deferoxamine for 3 consecutive days. Patients will receive an intravenous dose
of 32 mg/kg/day.
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • 18-85 years old inclusive, • Subarachnoid hemorrhage diagnosed by CT on admission, • No history of possible traumatic origin of subarachnoid hemorrhage, • Eligible for inclusion within 72 hours of subarachnoid hemorrhage, • Saccular intracranial aneurysm proven by cerebral angiography or CTA, • Surgical or endovascular obliteration is successfully performed, • Able to obtain written informed consent from patient or surrogate, • Patients in good clinical grade (WFNS 1-3) (GCS 13-15) at time of inclusion.
Exclusion criteria
Exclusion criteria: • Pregnancy, as confirmed by routine urine test on admission, • Abnormal renal function at time of inclusion (eGFR 35 U/L and ALT > 45 U/L.) • History of liver disease or active liver or renal disease, • Patients with low ferritine (30), o SpO2 30) o Acidosis (pH
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint is the occurrence of DCI | — |
Secondary
| Measure | Time frame |
|---|---|
| Secundary endpoint is the total number of patients with drug related adverse events. | — |
Countries
Netherlands
Outcome results
None listed